Information, not a decision

Lung cancer: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 12 Nov 2026

Open trials (3114)

NCT07928258	Phase 1	A Study of LY4336619 in Adult Participants With Advanced Solid Tumors	Not yet recruiting
NCT07902921	Phase 1/2	STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma	Not yet recruiting
NCT03340506	Phase 4	Dabrafenib and/or Trametinib Rollover Study	Recruiting
NCT07843940	Phase 1/2	A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)	Recruiting
NCT04557449	Phase 2	Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Recruiting
NCT07503808	Phase 1	A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types	Recruiting
NCT06868485	Phase 2	A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer	Recruiting
NCT06646276	Phase 3	A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).	Recruiting
NCT07099898	Phase 3	A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]	Recruiting
NCT06345729	Phase 3	A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)	Recruiting
NCT07472517	Phase 3	DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy	Recruiting
NCT07206498	Phase 1/2	A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC	Recruiting

3102 more in the doctor's list on the site.

Phase 3 trials that ended in the last 90 days

NCT05132075	5 Oct 2026	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer	Stopped early
NCT04129502	22 Sept 2026	TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations	Completed
NCT02273375	1 Sept 2026	Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC	Completed
NCT02486718	26 Aug 2026	Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]	Completed
NCT04956692	24 Aug 2026	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Completed

Guidelines

ESMO Clinical Practice Guidelines
NCCN Guidelines
[Interpretation of the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer.

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 12 Nov 2026

https://frontlightresearch.com/en/doctor/lung-cancer/tumor-board